0001714899-24-000060.txt : 20240215 0001714899-24-000060.hdr.sgml : 20240215 20240215211442 ACCESSION NUMBER: 0001714899-24-000060 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240213 FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ho Carole CENTRAL INDEX KEY: 0001724605 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 24645604 MAIL ADDRESS: STREET 1: C/O DENALI THERAPEUTICS INC. STREET 2: 151 OYSTER POINT BLVD., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 wk-form4_1708049673.xml FORM 4 X0508 4 2024-02-13 0 0001714899 Denali Therapeutics Inc. DNLI 0001724605 Ho Carole C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer 1 Common Stock 2024-02-13 4 S 0 2784 17.29 D 145010 D Common Stock 2024-02-14 4 S 0 1405 17.79 D 143605 D Common Stock 183219 I See footnote Common Stock 25000 I See footnote Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Includes 129,435 RSUs. The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29,2023. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.55 to $17.94 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children. /s/ Tyler Nielsen, by power of attorney 2024-02-15